EOF Warns Consumers About Unapproved Product Sold as Joint Pain Treatment
Concerns were raised on 09.01.2026 by the Greek National Organization for Medicines after reports surfaced regarding the online promotion of a product marketed as a remedy for joint discomfort. Clarification followed from the authority stating that the item known as Artizynt has never been approved as a pharmaceutical product.
Further attention was drawn to claims suggesting that Artizynt provides relief from pain, supports inflammation reduction, and assists with recovery after injuries. Information released by EOF highlights that none of these promises have undergone any official safety or effectiveness evaluation.
Details shared by the organization confirm that the product is being distributed through the website ygeiaevexia.gr/farma. Uncertainty surrounds the identity of the company responsible for its marketing or distribution in Greece.
Guidance from EOF urges consumers to avoid using Artizynt under any circumstances. Additional instructions encourage the public to immediately notify the authority if the product comes into their possession.
Official EOF Announcement
The official statement emphasizes the misleading presentation of Artizynt, which is advertised online as a treatment intended to ease joint pain, reduce inflammation, and aid in post injury recovery. According to EOF, the product lacks approval and has not been subjected to safety or efficacy assessments.
The agency also underlines that Artizynt is being promoted and sold illegally within Greece through the website ygeiaevexia.gr/farma, while the responsible company remains unknown.
Consumers are asked to remain vigilant and to refrain from using the product. EOF also requests that any individual who obtains Artizynt should promptly inform the organization.
